Summary

The global market for Iloprost Drugs was estimated to be worth US$ 62.34 million in 2024 and is forecast to a readjusted size of US$ 44.98 million by 2031 with a CAGR of -4.6% during the forecast period 2025-2031.
Iloprost is a drug used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and other diseases in which the blood vessels are constricted and blood can't flow to the tissues.In 2024, global Iloprost drug production reached approximately 1.04 m units, with an average global market price of around US$ 60 per unit.

In recent years, pulmonary arterial hypertension (PAH) and related vascular diseases have been designated as public health priorities in many countries and regions, with governmental and regulatory bodies updating clinical guidelines to improve diagnosis rates and early intervention. This creates institutional channels for broader adoption of Iloprost. Notably, the US FDA’s approval of Iloprost injection (Aurlumyn) for severe frostbite to reduce the risk of amputation marks a landmark extension beyond traditional PAH indications, boosting confidence among pharmaceutical companies and investors in its potential in new therapeutic areas. In addition, healthcare providers’ increased emphasis on improving microcirculation and reducing vascular resistance to enhance patient outcomes, together with rising demand from patients and clinicians for both chronic maintenance and acute intervention therapies, propel innovation in delivery modes (inhalation, intravenous) and device convenience. Generic entry and lifecycle management in some jurisdictions also contribute to cost reduction and increased access.

Even with strong growth potential, Iloprost faces several constraints. The cost of treatment is relatively high, especially when specialized inhalation or nebulization devices, infusion systems, or hospital-based administration are required; insurance or reimbursement coverage varies widely between countries, which may hinder uptake and accessibility. The side effect profile and tolerability issues (hypotension, flushing, cough or airway irritation, headache, etc.) require careful clinical monitoring and dosing adjustments, which may reduce convenience and patient compliance. Regulatory pathways for new indications can be lengthy, and demonstrating safety and efficacy in novel applications demands robust clinical evidence; meanwhile, patent expirations and generic competition pose threats to established branded products’ margins. Also, the infrastructure burden—devices, delivery systems, distribution/logistics, cold chain where applicable—pose challenges, especially in emerging or low-resource markets.

Clinically and from the patient perspective, demand for Iloprost is moving toward greater diversity, personalization, and convenience. Physicians and patients increasingly expect Iloprost to address both chronic management (such as in PAH) and acute interventions (such as frostbite or vascular injury), with rapid onset of action and measurable improvements in life quality. Improvements in inhaled formulations—smaller, more portable nebulizers, fewer daily doses, better user-friendly inhaler systems—are emerging as strong demand points. Patient adherence vs long-term efficacy balance is of growing importance. Clinician interest in combination therapies with other PAH agents, or exploring supportive/adjuvant use in ischemic or circulatory-deficit conditions, is increasing. In emerging markets, as public insurance / health systems expand, demand for cost-effective versions or generic Iloprost increases significantly. Concurrently, there is rising anticipation for regulatory recognition of new indications and supportive clinical trials in frostbite, vascular skin disorders, and microcirculation-related conditions.

The upstream raw materials and manufacturing processes deeply affect Iloprost’s quality, cost, and supply stability. Synthesis of Iloprost involves high-purity organic chemical intermediates encompassing bicyclic ring systems, unsaturated carbon chains, hydroxyl and alkene functional groups, and the specific prostacyclin-analogous framework, requiring strict control of stereochemistry and impurity profile (including isomers, residual metal catalysts, solvent residues, etc.). Moreover, formulations for inhaled or intravenous use demand excipients, solvents, buffer systems, stabilizers that meet high purity and pharmacopeial / GMP standards. Key catalysts, metal complexes, fine chemical intermediates and solvents may be limited by raw material scarcity, environmental regulation (especially organic solvent emissions and waste disposal), import/export controls, and supplier qualification and certification requirements. The materials used in inhalation devices (plastic components, nebulizer heads, filters, etc.) and their environmental stability also affect production investment and overall cost structure.The gross profit margin of this product is around 80%.
This report aims to provide a comprehensive presentation of the global market for Iloprost Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Iloprost Drugs by region & country, by Type, and by Application.

The Iloprost Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Iloprost Drugs.

Market Segmentation
By Company
Actelion (J & J)
Bayer AG
Teva
Eastpharma
Zentiva
Segment by Type
Inhaled
Intravenous
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Iloprost Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Iloprost Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Iloprost Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Iloprost Drugs Product Introduction
1.2 Global Iloprost Drugs Market Size Forecast (2020-2031)
1.3 Iloprost Drugs Market Trends & Drivers
1.3.1 Iloprost Drugs Industry Trends
1.3.2 Iloprost Drugs Market Drivers & Opportunity
1.3.3 Iloprost Drugs Market Challenges
1.3.4 Iloprost Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Iloprost Drugs Players Revenue Ranking (2024)
2.2 Global Iloprost Drugs Revenue by Company (2020-2025)
2.3 Key Companies Iloprost Drugs Manufacturing Base Distribution and Headquarters
2.4 Key Companies Iloprost Drugs Product Offered
2.5 Key Companies Time to Begin Mass Production of Iloprost Drugs
2.6 Iloprost Drugs Market Competitive Analysis
2.6.1 Iloprost Drugs Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Iloprost Drugs Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Iloprost Drugs as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Inhaled
3.1.2 Intravenous
3.2 Global Iloprost Drugs Sales Value by Type
3.2.1 Global Iloprost Drugs Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Iloprost Drugs Sales Value, by Type (2020-2031)
3.2.3 Global Iloprost Drugs Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.2 Global Iloprost Drugs Sales Value by Application
4.2.1 Global Iloprost Drugs Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Iloprost Drugs Sales Value, by Application (2020-2031)
4.2.3 Global Iloprost Drugs Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Iloprost Drugs Sales Value by Region
5.1.1 Global Iloprost Drugs Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Iloprost Drugs Sales Value by Region (2020-2025)
5.1.3 Global Iloprost Drugs Sales Value by Region (2026-2031)
5.1.4 Global Iloprost Drugs Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Iloprost Drugs Sales Value, 2020-2031
5.2.2 North America Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Iloprost Drugs Sales Value, 2020-2031
5.3.2 Europe Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Iloprost Drugs Sales Value, 2020-2031
5.4.2 Asia Pacific Iloprost Drugs Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Iloprost Drugs Sales Value, 2020-2031
5.5.2 South America Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Iloprost Drugs Sales Value, 2020-2031
5.6.2 Middle East & Africa Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Iloprost Drugs Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Iloprost Drugs Sales Value, 2020-2031
6.3 United States
6.3.1 United States Iloprost Drugs Sales Value, 2020-2031
6.3.2 United States Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Iloprost Drugs Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Iloprost Drugs Sales Value, 2020-2031
6.4.2 Europe Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Iloprost Drugs Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Iloprost Drugs Sales Value, 2020-2031
6.5.2 China Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
6.5.3 China Iloprost Drugs Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Iloprost Drugs Sales Value, 2020-2031
6.6.2 Japan Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Iloprost Drugs Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Iloprost Drugs Sales Value, 2020-2031
6.7.2 South Korea Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Iloprost Drugs Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Iloprost Drugs Sales Value, 2020-2031
6.8.2 Southeast Asia Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Iloprost Drugs Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Iloprost Drugs Sales Value, 2020-2031
6.9.2 India Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
6.9.3 India Iloprost Drugs Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Actelion (J & J)
7.1.1 Actelion (J & J) Profile
7.1.2 Actelion (J & J) Main Business
7.1.3 Actelion (J & J) Iloprost Drugs Products, Services and Solutions
7.1.4 Actelion (J & J) Iloprost Drugs Revenue (US$ Million) & (2020-2025)
7.1.5 Actelion (J & J) Recent Developments
7.2 Bayer AG
7.2.1 Bayer AG Profile
7.2.2 Bayer AG Main Business
7.2.3 Bayer AG Iloprost Drugs Products, Services and Solutions
7.2.4 Bayer AG Iloprost Drugs Revenue (US$ Million) & (2020-2025)
7.2.5 Bayer AG Recent Developments
7.3 Teva
7.3.1 Teva Profile
7.3.2 Teva Main Business
7.3.3 Teva Iloprost Drugs Products, Services and Solutions
7.3.4 Teva Iloprost Drugs Revenue (US$ Million) & (2020-2025)
7.3.5 Teva Recent Developments
7.4 Eastpharma
7.4.1 Eastpharma Profile
7.4.2 Eastpharma Main Business
7.4.3 Eastpharma Iloprost Drugs Products, Services and Solutions
7.4.4 Eastpharma Iloprost Drugs Revenue (US$ Million) & (2020-2025)
7.4.5 Eastpharma Recent Developments
7.5 Zentiva
7.5.1 Zentiva Profile
7.5.2 Zentiva Main Business
7.5.3 Zentiva Iloprost Drugs Products, Services and Solutions
7.5.4 Zentiva Iloprost Drugs Revenue (US$ Million) & (2020-2025)
7.5.5 Zentiva Recent Developments
8 Industry Chain Analysis
8.1 Iloprost Drugs Industrial Chain
8.2 Iloprost Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Iloprost Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Iloprost Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer